VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SKINThe Beauty Health Company
$0.66$86M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSKINCash Flow

The Beauty Health Company (SKIN) Cash Flow Statement

7Y historyFree accessUpdated daily

Liquidity is under pressure as the company burned through cash reserves, evidenced by a $9.1 million working capital outflow in 2026Q1 and erratic OCF/NI ratios.

SKIN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations28.93M37.5M16.13M21.75M-106.6M-28.36M-12.44M1.73M
Operating CF Margin %-12.47%4.83%5.46%-29.14%-10.9%-10.44%1.04%
Operating CF Growth %-244.05%132.43%-25.82%120.4%-275.87%-128.06%-819.68%-
Net Income-6.02M-9.5M-29.1M-100.12M44.38M-375.11M-29.18M-1.64M
Depreciation & Amortization17.6M033.68M34.67M22.02M21.14M14.4M13.88M
Stock-Based Compensation11.35M026.7M22.54M28.5M12.42M363K103K
Deferred Taxes409K0-3.75M0-1.79M-3.76M-4.34M-4.65M
Other Non-Cash Items9.9M36.63M16M41.29M-59.42M335.62M8.9M1.94M
Working Capital Changes-4.29M10.37M-27.39M23.36M-140.28M-18.66M-2.58M-7.91M
Change in Receivables3.67M8.59M20.8M12.85M-32.02M-31.01M3.7M-11.05M
Change in Inventory11.89M15.8M-10.5M19.57M-82.1M-9.44M-3.21M-4.77M
Change in Payables-13.59M-7.2M-43.78M15.78M1.61M10.52M4.89M4.31M
Cash from Investing-5.67M-5.16M-6.79M-31.51M-18.87M-37.73M-3.82M-12.48M
Capital Expenditures-121K-5.16M-6.79M-13.05M-17.39M-15.62M-3.82M-10.42M
CapEx % of Revenue0.04%1.72%2.03%3.28%4.75%6%3.21%6.25%
Acquisitions000-18.46M-1.48M-22.9M0-2.06M
Investments--------
Other Investing-5.55M0000781K00
Cash from Financing-195.58M-174.9M-158.34M-37.45M-205.24M959.03M18.27M14.58M
Debt Issued (Net)-431.82M-173.35M-156.08M00524.51M19.73M16.5M
Equity Issued (Net)-895K-1.57M-1.96M-35.63M-160M938.38M-154K0
Dividends Paid00000000
Share Repurchases-895K0-1.96M-32.4M-160M0-154K0
Other Financing237.14M26K-302K-1.82M-45.24M-503.86M-1.3M-1.92M
Net Change in Cash-168.66M-137.4M-152.96M-45.17M-333.69M892.4M2.18M3.73M
Free Cash Flow28.45M37.18M9.34M8.7M-123.99M-43.98M-16.25M-8.69M
FCF Margin %9.61%12.36%2.79%2.19%-33.89%-16.91%-13.65%-5.22%
FCF Growth %-4.69%298.09%7.34%107.02%-181.95%-170.58%-86.94%-
FCF per Share0.220.270.070.07-0.83-0.43-0.47-0.27
FCF Conversion (FCF/Net Income)-4.72x-3.94x-0.55x-0.22x-2.41x0.07x0.43x-1.05x
Interest Paid008.01M9.38M010.25M13.54M15.73M
Taxes Paid002.8M2.27M01.7M2.43M861K

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Hardware reliability and adoption

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Masked by Volatility

As reported in quarterly filings, the relationship between net income and operating cash flow is highly erratic, with OCF/NI ratios swinging from 30.70 in 2024Q2 to -1.88 in 2025Q4, indicating that reported earnings are currently poor proxies for the company's actual cash-generating capacity.

The persistent gap between net income and operating cash flow suggests that significant non-cash charges and working capital fluctuations are distorting the bottom line. Investors should monitor whether these discrepancies stem from aggressive revenue recognition or the ongoing costs associated with hardware warranty reserves.

Free Cash Flow Remains Unstable

Based on the provided cash flow data, FCF margins have exhibited extreme instability, ranging from a low of -22.9% in 2024Q1 to a peak of 18.7% in 2024Q4, highlighting the company's struggle to maintain consistent cash generation amidst its current operational turnaround.

The inability to sustain positive free cash flow suggests that the business model is currently sensitive to lumpy capital equipment sales rather than predictable consumable replenishment. This volatility warrants further investigation into whether the company can achieve self-sustaining cash flow without further external financing.

Working Capital Swings Impair Liquidity

According to the cash flow statements, working capital changes have been a major source of cash flow volatility, with a significant $9.1 million outflow in 2026Q1 following a $7.9 million inflow in 2025Q4, reflecting inconsistent efficiency in managing inventory and accounts receivable.

These erratic working capital movements suggest that the company may be struggling to align its inventory levels with actual demand for its delivery systems. Such fluctuations may indicate potential build-ups of obsolete hardware or difficulties in collecting payments from med-spa partners during periods of market stress.

Capital Allocation Lacks Strategic Focus

As evidenced by historical cash flow data, the company has prioritized significant share repurchases, including $156.1 million in 2024Q4, despite facing negative operating margins and revenue contraction, which appears to be a questionable use of capital given the firm's current operational challenges.

The decision to return capital to shareholders while the core business is burning cash suggests a potential misalignment between management's capital allocation strategy and the company's underlying financial health. This pattern of deployment may limit the firm's ability to fund necessary R&D or address hardware reliability issues.

SKIN — Frequently Asked Questions

Quick answers to the most common questions about buying SKIN stock.

How much cash does The Beauty Health Company (SKIN) generate from operations?

The Beauty Health Company (SKIN) generated $37.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is The Beauty Health Company's free cash flow?

The Beauty Health Company (SKIN) generated $37.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is The Beauty Health Company's capital expenditure (CapEx)?

The Beauty Health Company (SKIN) spent $5.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.